Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.55 |
| ▸ | GSK3B | P49841 | 11/20 | 0.55 |
| ▸ | WNT1 | P04628 | 4/20 | 0.55 |
| ▸ | WNT3A | P56704 | 3/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RIOK2 | Q9BVS4 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | CLK3 | P49761 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559364 | 0.87 | MAPK8 (0.70) | MAPK8DYRK1AGSK3BWNT1WNT3A | |
| SCHEMBL10165890 | 0.86 | WNT3A (0.59) | MAPK8DYRK1AGSK3BWNT1WNT3A | |
| SCHEMBL557622 | 0.84 | MAPK8 (0.70) | MAPK8DYRK1AGSK3BWNT1WNT3A | |
| SCHEMBL559231 | 0.83 | MAPK8 (1.00) | MAPK8DYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL10165891 | 0.82 | MAPK8 (0.53) | MAPK8DYRK1AGSK3BWNT1 | |
| SCHEMBL12361577 | 0.79 | MAPK8 (0.67) | MAPK8DYRK1AGSK3BWNT1WNT3A | |
| SCHEMBL559695 | 0.78 | MAPK8 (0.58) | MAPK8DYRK1AGSK3BWNT1WNT3A | |
| SCHEMBL558470 | 0.76 | MAPK8 (0.56) | MAPK8DYRK1AGSK3BWNT1WNT3A | |
| SCHEMBL10165902 | 0.75 | DYRK1A (0.55) | DYRK1AGSK3BWNT1 | |
| SCHEMBL559024 | 0.74 | DYRK1A (0.65) | MAPK8DYRK1AGSK3BWNT1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MAPK8 20/4885DYRK1A 1064/4885GSK3B 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.